论文部分内容阅读
目的探讨瑞舒伐他汀和阿托伐他汀对冠心病患者的临床疗效及对血清中白介素-35(IL-35)、核因子-κB(NF-κB)水平的影响。方法选取100例冠心病患者,根据使用药物不同分为两组,对照组(49例)口服阿托伐他汀钙片,观察组(51例)口服瑞舒伐他汀钙片,通过治疗前后的血脂水平,IL-35、NF-κB水平及治疗期间不良反应发生情况,评价不同他汀类药物对冠心病患者的临床疗效差异。结果治疗前,两组三酰甘油(TG)、总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)水平相比,无统计学差异;治疗后,两组TG、TC、LDL-C水平均降低,同组治疗前后比较差异有统计学意义(P<0.05);且观察组LDL-C水平低于对照组,差异有统计学意义(P<0.05),TG、TC水平比较无统计学差异;两组HDL-C水平均升高,同组治疗前后比较差异有统计学意义(P<0.05),但组间比较无统计学差异。治疗前,两组血清IL-35、NF-κB水平相比,无统计学差异;治疗后,两组患者血清IL-35水平均升高,血清NF-κB水平均降低,同组治疗前后比较差异有统计学意义(P<0.05);且观察组IL-35水平明显高于对照组,NF-κB水平明显低于对照组,差异有统计学意义(P<0.05)。治疗期间,两组不良反应率无统计学差异。结论瑞舒伐他汀和阿托伐他汀对冠心病均具有较好的调脂作用,瑞舒伐他汀对LDL-C的降低效果更明显,此外,瑞舒伐他汀能更好地控制体内炎症反应,不良反应少,是临床治疗冠心病的理想药物。
Objective To investigate the clinical effects of rosuvastatin and atorvastatin on the levels of serum interleukin-35 (IL-35) and nuclear factor-κB (NF-κB) in patients with coronary heart disease. Methods 100 patients with coronary heart disease were selected and divided into two groups according to the different drugs used. In the control group (49 cases), atorvastatin calcium tablets were orally administered. In the observation group (51 cases), rosuvastatin calcium tablets were administered orally. Level, IL-35, NF-κB levels and the incidence of adverse reactions during treatment to evaluate the different clinical efficacy of statins in patients with coronary heart disease. Results Before treatment, there was no significant difference between the two groups in TG, TC, LDL-C and HDL-C levels. Treatment (P <0.05). The levels of LDL-C in the observation group were lower than those in the control group (P <0.05), while the levels of TG, TC and LDL-C in the two groups were significantly decreased <0.05). There was no significant difference in TG and TC levels between the two groups. The levels of HDL-C in both groups were significantly increased (P <0.05), but there was no significant difference between the two groups. Before treatment, the levels of serum IL-35 and NF-κB were not significantly different between the two groups. After treatment, serum IL-35 levels and serum NF-κB levels were decreased in both groups before and after treatment (P <0.05). The level of IL-35 in the observation group was significantly higher than that in the control group, and the level of NF-κB in the observation group was significantly lower than that in the control group (P <0.05). During treatment, there was no significant difference in adverse reactions between the two groups. Conclusion Rosuvastatin and atorvastatin have better lipid-lowering effects on coronary heart disease, rosuvastatin on LDL-C decreased more significantly, in addition, rosuvastatin can better control the inflammation in vivo , Less adverse reactions, is the ideal drug for clinical treatment of coronary heart disease.